Grigory V. Volchenkov

Grigory V. Volchenkov

Auto-generated profile, based on publicly available information

Grigory V. Volchenkov

Vladimir Regional TB Control Center , Vladimir

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 March 2021 in Photochemistry and Photobiology
Verified
Journal Article
Closed access
PDF file
GVGrigory Volchenkov
Grigory Volchenkov


3 February 2026 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
ASAlexandra V Solovyeva
Alexandra V Solovyeva
GVGrigory V Volchenkov
Grigory V Volchenkov
OPOksana I Ponomarenko
Oksana I Ponomarenko
TKTatiana A Kuznezova
Tatiana A Kuznezova
TSTatiana R Somova
Tatiana R Somova
SKSalmaan Keshavjee
Salmaan Keshavjee
Background: Rates of drug-resistant tuberculosis (DR-TB) are increasing worldwide. Tuberculosis preventive treatment (TPT) for contacts of people with active TB is essential to halt infection progression and transmission. While newer TPT regimens for exposure to drug-susceptible and rifampin (R)-resistant strains (MDR-TB/RR-TB) are expanding, optimal treatment for contacts exposed to fluoroquinolone-resistant strains of TB (pre-XDR- or XDR-TB) remains unclear. In 2019–2020, Vladimir City, Russia, introduced moxifloxacin (Mfx)- and bedaquiline (Bdq)-based TPT regimens to prevent disease development in contacts exposed to MDR/RR-TB and pre-XDR-TB. Methods: We conducted a retrospective cohort study of adult TB contacts, people experiencing homelessness, and people with HIV who received TPT in Vladimir between 2019 and 2020. Those without TB disease but with indications for TPT were offered 1 of 6 regimens, based on drug-susceptibility testing results of the index patient: rifapentine/isoniazid (3HP), isoniazid (6H), rifabutin/isoniazid (3HRb), 4R, 4Mfx, or 3Bdq. Adverse drug reactions (ADRs) were monitored with monthly lab tests and electrocardiogram (ECGs). Outcome measures included ADRs, TPT completion, and TB disease incidence during the 12-month follow-up period. Results: Over 24 months, 403 people started TPT. No life-threatening ADRs or deaths occurred. The lowest ADR rate and highest completion were seen with 3Bdq (95.2%) compared to 3HP (75.9%, Mid-P exact = .03). Tuberculosis incidence per 1000 person-years was 4 times higher among eligible individuals who declined TPT versus those initiating it. Conclusions: Preventive therapy for drug-resistant TB, including fluoroquinolone-resistant strains, is acceptable, safe, and effective. Implementation of comprehensive TPT programs in high-burden DR-TB settings can protect contacts and reduce transmission.

7 July 2025 in Annals of the Russian academy of medical sciences
Verified
Journal Article
Closed access
PDF file
EKElena S. Khimova
Elena S. Khimova
GVGrigory V. Volchenkov
Grigory V. Volchenkov
DPDmitry V. Perkhin
Dmitry V. Perkhin
EDElena S. Dyzhik
Elena S. Dyzhik
OSOksana M. Sveshnikova
Oksana M. Sveshnikova
МОМарьяндышев Андрей Олегович
Марьяндышев Андрей Олегович
Background. The World Health Organization (WHO) recommends conducting regional operational studies of fully oral modified shorter treatment regimens for multidrug/rifampicin-resistant tuberculosis in different countries to achieve an indicator of tuberculosis treatment effectiveness. Aims — to evaluate the efficacy and safety of 9-month, fully oral four-component treatment regimen for patients with MDR and pre-XDR-TB in two administrative regions of the Russian Federation. Methods. In frame of operational research conducted in the Arkhangelsk and Vladimir regions, 167 MDR-TB patients started 9-month treatment. Based on results of drug susceptibility testing of mycobacteria to fluoroquinolones, 134 participans received therapy with combination of levofloxacin (Lfx), bedaquiline (Bdq), linezolid (Lzd), clofazimine (Cfz), one patient — with levofloxacin (Lfx), bedaquiline (Bdq), delamanid (Dlm), clofazimine (Cfz), and 32 patients with — bedaquiline (Bdq), linezolid (Lzd), delamanid (Dlm) and clofazimine (Cfz). The molecular genetic verification of MDR-TB was 98.2%. HIV and hepatitis C co-infection was confirmed for 13.2% and 16.8% of participants, respectively. Adults, two teenagers and a pregnant woman participated in the study. Results. Favorable treatment outcomes were registered for 137 (82%) patients. Two of them had recurrence of the active TB disease. 15 (9%) patients were lost-to-follow-up, 7 (4.2%) patients had failure outcomes, and 8 (4.8%) patients died during treatment. On average, the culture conversion occurred after the first month of treatment. Active safety monitoring revealed 483 adverse events in 167 patients, the most frequent were: hepatotoxic reaction (in 89 patients, 53.3%), anemia (in 62 patients, 37.1%), QT prolongation (in 41 patients, 24.6%), polyneuropathy (in 45 patients, 26.9%). The frequency of serious adverse events was 9.5% of total number of adverse events. Conclusions. The results of an operational study of fully oral 9-month four-component treatment regimens demonstrate the achievement of WHO tuberculosis treatment effectiveness indicators (more than 80%), and low level of serious adverse events. They can be recommended for the national clinical guidelines.

10 March 2025 in medRxiv
Verified
Preprint
Open access
PDF file
ASAlexandra V. Solovyeva
Alexandra V. Solovyeva
GVGrigory V. Volchenkov
Grigory V. Volchenkov
OPOksana I. Ponomarenko
Oksana I. Ponomarenko
TKTatiana A. Kuznezova
Tatiana A. Kuznezova
TSTatiana R. Somova
Tatiana R. Somova
SKSalmaan Keshavjee
Salmaan Keshavjee
Introduction: Rates of drug-resistant tuberculosis (TB) are increasing worldwide. TB preventive treatment (TPT) for contacts of active TB patients is essential to halt infection progression and transmission. While newer TPT regimens for drug-sensitive strains are expanding, optimal treatment for contacts exposed to drug-resistant TB (DR-TB) remains unclear. In 2019-2020, Vladimir City, Russia, introduced moxifloxacin and bedaquiline-based TPT regimens to prevent disease development in contacts exposed to DR-TB. Methods: We conducted a retrospective cohort study using medical records data that included adult TB contacts, people experiencing homelessness, and persons with HIV who received TPT in Vladimir City, Russia, between 2019 and 2020. Those without TB disease but with indications for TPT were offered one of six regimens, based on drug-susceptible testing results of index patient: Rifapentine/Isoniazid (3HP), Isoniazid (6H), Rifabutin/Isoniazid (3HRb), Rifampicin (4R), Moxifloxacin (4Mfx), or Bedaquiline (3Bdq). Adverse drug reactions (ADRs) were monitored with monthly lab tests and ECGs. Results: Over 24 months, 403 people started TPT. No life-threatening ADRs or deaths occurred. The lowest ADR rate and significantly higher completion rate was observed in 3Bdq (n=20, 95.2%) compared to 3HP (n=192, 75.9%, Mid-P exact = .03). The rate of TB disease per 1,000 person-years of observation was four times higher in individuals eligible for TPT who did not start it compared to those who initiated TPT. Conclusion: Treatment for the prevention of DR-TB, including forms resistant to rifampicin and fluoroquinolones, is feasible, effective and safe. This study introduces a novel paradigm for TB prevention in high-burden DR-TB settings, offering a promising strategy to protect contacts and reduce transmission. Key points: Moxifloxacin and bedaquiline are safe, effective, and feasible agents for preventive therapy among contacts of individuals with drug-resistant tuberculosis (TB) and can be used as part of the comprehensive search-treat-prevent approach for TB elimination.

12 March 2025 in Tuberculosis and Lung Diseases
Verified
Journal Article
Open access
PDF file
ASA. V. Solovyova
A. V. Solovyova
NKN. V. Kuteneva
N. V. Kuteneva
TKT. A. Kuznetsova
T. A. Kuznetsova
EBE. V. Belova
E. V. Belova
EDE. S. Dyuzhik
E. S. Dyuzhik
GVG. V. Volchenkov
G. V. Volchenkov
The objective: to estimate the proportion of those lost to follow-up at individual stages of the cascade medical care for tuberculosis infection, to identify factors influencing these losses.Subjects and Methods. A total of 810 homeless individuals were included in the prospective cohort study from January 1, 2019 to December 31, 2022. When active tuberculosis (TB) was ruled out and indications for preventive anti-tuberculosis therapy (PTBT) were established, the optimal regimen for the patient was suggested. After completion of preventive anti-tuberculosis therapy, follow-up of patients continued for at least 12 months. By the end of follow-up, patients underwent control chest X-ray to detect tuberculosis manifestations.Results. Of the 810 people included in the study, 207 (25.6%) received preventive treatment of tuberculosis. Of them, 77/207 (37.2%) did not start a course of preventive treatment (loss to follow-up). The age of 28-37 years, alcohol addiction, and positive HIV status were associated with the biggest loss at this stage. Of the 130 people who started preventive treatment, 42 (32.3%) did not complete the full course of treatment. However, the chances of incomplete treatment on regimens of three months or longer were 5.4 (CI: 2.2-15.4) times higher versus a one-month regimen. The biggest loss of 64/88 (72.7%) cases was recorded during the follow-up period (after completion of preventive treatment). No tuberculosis cases were detected among those who received the full course of preventive treatment. While among those who refused or interrupted preventive therapy, 3 cases of tuberculosis were diagnosed.